{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1%2C+Placebo+Group&page=11", "query": { "intervention": "Part 1, Placebo Group", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 279, "total_pages": 28, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1%2C+Placebo+Group&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1%2C+Placebo+Group&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T09:50:45.785Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00141024", "title": "Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "EP HIV-1043", "type": "BIOLOGICAL" }, { "name": "EP HIV-1090", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 84, "start_date": "2006-01", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-10-15T09:50:45.785Z", "location_count": 3, "location_summary": "San Francisco, California • Baltimore, Maryland • Rochester, New York", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00141024" }, { "nct_id": "NCT02542605", "title": "To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "Erenumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "PACAP-38 Challenge Agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 35, "start_date": "2015-11-11", "completion_date": "2017-11-08", "has_results": true, "last_update_posted_date": "2019-06-03", "last_synced_at": "2026-10-15T09:50:45.785Z", "location_count": 1, "location_summary": "Anaheim, California", "locations": [ { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02542605" }, { "nct_id": "NCT01369485", "title": "Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Overactive Bladder" ], "interventions": [ { "name": "(VERV™ System)", "type": "DEVICE" }, { "name": "Sham version of (VERV™ System)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Ethicon Endo-Surgery", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 163, "start_date": "2011-06", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2014-09-11", "last_synced_at": "2026-10-15T09:50:45.785Z", "location_count": 14, "location_summary": "Tucson, Arizona • Murrieta, California • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Murrieta", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Naples", "state": "Florida" }, { "city": "Pompano Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01369485" }, { "nct_id": "NCT03016325", "title": "Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "HNO Donor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2017-01-13", "completion_date": "2019-11-12", "has_results": true, "last_update_posted_date": "2021-01-06", "last_synced_at": "2026-10-15T09:50:45.785Z", "location_count": 24, "location_summary": "Tucson, Arizona • Gainesville, Florida • Tampa, Florida + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03016325" }, { "nct_id": "NCT02911818", "title": "Lifestyle Modification and Liraglutide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "CMS-recommended lifestyle counseling", "type": "BEHAVIORAL" }, { "name": "Liraglutide 3.0mg", "type": "DRUG" }, { "name": "Portion-Controlled Diet", "type": "OTHER" }, { "name": "Placebo Oral Tablet", "type": "DRUG" }, { "name": "Phentermine 15 MG", "type": "DRUG" }, { "name": "Extension Study CMS-recommended lifestyle counseling", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL", "DRUG", "OTHER" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 150, "start_date": "2016-09", "completion_date": "2018-12", "has_results": true, "last_update_posted_date": "2019-05-07", "last_synced_at": "2026-10-15T09:50:45.785Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02911818" }, { "nct_id": "NCT02317640", "title": "TRT in Combination With Electrical Stimulation and Standing: Effect on Muscle and Bone in Spinal Cord Injured Males", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Spinal Cord Injury" ], "interventions": [ { "name": "Testosterone Gel applied by a pump", "type": "DRUG" }, { "name": "Stand Training", "type": "OTHER" }, { "name": "Electrical Stimulation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "OTHER", "DEVICE" ], "sponsor": "Kessler Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "58 Years", "sex": "MALE", "summary": "18 Years to 58 Years · Male only" }, "enrollment_count": 56, "start_date": "2017-03-15", "completion_date": "2022-10", "has_results": false, "last_update_posted_date": "2017-08-22", "last_synced_at": "2026-10-15T09:50:45.785Z", "location_count": 1, "location_summary": "West Orange, New Jersey", "locations": [ { "city": "West Orange", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02317640" }, { "nct_id": "NCT02091206", "title": "A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epilepsy", "Dravet Syndrome" ], "interventions": [ { "name": "GWP42003-P 5 mg/kg/day Dose", "type": "DRUG" }, { "name": "Placebo control", "type": "DRUG" }, { "name": "GWP42003-P 10 mg/kg/day Dose", "type": "DRUG" }, { "name": "GWP42003-P 20 mg/kg/day Dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "10 Years", "sex": "ALL", "summary": "4 Years to 10 Years" }, "enrollment_count": 34, "start_date": "2014-10-22", "completion_date": "2015-03-09", "has_results": true, "last_update_posted_date": "2022-09-28", "last_synced_at": "2026-10-15T09:50:45.785Z", "location_count": 8, "location_summary": "Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02091206" }, { "nct_id": "NCT02315417", "title": "An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pyoderma Gangrenosum" ], "interventions": [ { "name": "gevokizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "gevokizumab open-label", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "XOMA (US) LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2014-11", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2016-04-27", "last_synced_at": "2026-10-15T09:50:45.785Z", "location_count": 12, "location_summary": "Coral Gables, Florida • North Miami Beach, Florida • Ann Arbor, Michigan + 9 more", "locations": [ { "city": "Coral Gables", "state": "Florida" }, { "city": "North Miami Beach", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02315417" }, { "nct_id": "NCT03013998", "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Previously Untreated Relapsed Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Samalizumab (BAML-16-001-S1)", "type": "BIOLOGICAL" }, { "name": "BI 836858 (BAML-16-001-S2)", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Daunorubicin (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S2)", "type": "DRUG" }, { "name": "AG-221 (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Daunorubicin (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Pevonedistat (BAML-16-001-S9)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S9)", "type": "DRUG" }, { "name": "AG-120 (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "AZD5153 (BAML-16-001-S10)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S10)", "type": "DRUG" }, { "name": "TP-0903 (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "AZD5991 (BAML-16-001-S18)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S18)", "type": "DRUG" }, { "name": "SNDX-5613 (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 1)", "type": "DRUG" }, { "name": "ficlatuzumab (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S24)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 2)", "type": "DRUG" }, { "name": "Bleximenib (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Daunorubicin or Idarubicin (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Revumenib (BAML-16-001-S26/HO177)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S26/HO177)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Beat AML, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3000, "start_date": "2016-11", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-15T09:50:45.785Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03013998" }, { "nct_id": "NCT01483183", "title": "Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atrial Fibrillation", "Paroxysmal Atrial Fibrillation", "Persistent Atrial Fibrillation" ], "interventions": [ { "name": "OPC-108459", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 40, "start_date": "2011-11", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-04-10", "last_synced_at": "2026-10-15T09:50:45.785Z", "location_count": 9, "location_summary": "Washington D.C., District of Columbia • Hollywood, Florida • Jacksonville, Florida + 6 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01483183" } ] }